| Literature DB >> 23603254 |
S Wong1, C Hennequin, L Quero.
Abstract
The main indication of oesophageal brachytherapy is palliative: it can improve dysphagia in patients with a tumor not suitable for surgery or chemoradiotherapy. A randomized clinical trial showed that survival without dysphagia and quality of life was improved by endoluminal brachytherapy in comparison to self-expansible metallic stents. It also increases the duration of palliation after laser deobstruction. Its role as a curative treatment of locally advanced tumors is still discussed: in combination with external beam radiotherapy, it seems that brachytherapy increased the rate of severe toxicity (haemorrhages, fistula, stenosis). In superficial lesions, brachytherapy with or without external beam radiotherapy seems logical but large prospective studies are missing in this setting.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23603254 DOI: 10.1016/j.canrad.2013.03.003
Source DB: PubMed Journal: Cancer Radiother ISSN: 1278-3218 Impact factor: 1.018